title: Early interim FDG PET/CT prediction of treatment response and prognosis in pediatric Hodgkin disease-added value of low-dose CT.
abstract: BACKGROUND
  Interim 18F-FDG PET helps predict outcome and tailor treatment in adults with Hodgkin disease (HD).
  
  
  OBJECTIVE
  The purpose of this study was to assess predictive values of interim 18F-FDG PET/CT in children with HD and to define the potential added value to interim PET of low-dose CT.
  
  
  METHODS
  Children were prospectively enrolled August 2002-April 2007. PET/low-dose CT was performed at staging, after 2 cycles, at the end of treatment and during follow-up (mean 45 months). Treatment was unchanged regardless of interim results. PET and low-dose CT were read independently.
  
  
  RESULTS
  Of 34 enrolled children (ages 3-17 years), 27 achieved complete response, 4 had progressive disease and 3 had relapse. Interim PET alone had positive and negative predictive values of 67% and 89%, respectively. Interim low-dose CT alone had positive and negative predictive values of 35% and 100%, respectively. Interim PET/CT had positive and negative predictive values of 75% and 96%, respectively.
  
  
  CONCLUSIONS
  Early interim PET/CT was a good predictor of outcome. Integrated PET and low-dose CT improved the predictive value in children with HD.
authors.affiliation: Department of Diagnostic Imaging, Rambam Health Care Campus, Haifa, Israel. a_ilivitzki@rambam.health.gov.il
authors.forename: Anat
authors.initials: A
authors.lastname: Ilivitzki
authors.forename: Lea
authors.initials: L
authors.lastname: Radan
authors.forename: Miriam
authors.initials: M
authors.lastname: Ben-Arush
authors.forename: Ora
authors.initials: O
authors.lastname: Israel
authors.forename: Ayelet
authors.initials: A
authors.lastname: Ben-Barak
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D008297:Male; D064847:Multimodal Imaging; D009364:Neoplasm Recurrence, Local; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D011829:Radiation Dosage; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18